Select Page

Deculin 15mg tablets

Dexa Medica

Product packaging may vary from one country to another.

Ingredients in every tablet

Pioglitazone 15 mg

Each package contains

5 strips of 6 tablets

Other details

Dosage form:Tablet; plain
Flavour None

W.H.O. classification

ATC Level 1 A - Alimentary tract and metabolism
ATC Level 2 A10 - Drugs Used in Diabetes
ATC Level 3 A10B - Blood Glucose Lowering Drugs; excl. Insulins

Warnings

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Available in

Indonesia

Dosage information

0 TO 18 YEARS OLD
No data are available of pioglitazone in children and adolescents under 18 years of age, therefore pioglitazone should not be used for that patients.

18 TO 65 YEARS OLD
— Combination with metformin:
15-30 mg once daily. The current metformin dose can be continued upon initiation of pioglitazone therapy.

— Combination with sulfonylurea:
15-30 mg once daily. The current sulfonylurea dose can be continued upon initiation of pioglitazone therapy. If hypoglycemia occurs, the dose of the sulfonylurea should be decreased. If hypoglycemia occurs, the dose of the sulfonylurea should be decreased.

65 YEARS OLD AND ABOVE
No dose adjustment is necessary for elderly patients.

ADMINISTRATION
Should be taken once daily with or without food.

PATIENTS WITH IMPAIRED RENAL FUNCTION
No dose adjustment is necessary in patients with renal failure (creatinine clearance >4 ml/minute).

PATIENTS WITH IMPAIRED HEPATIC FUNCTION
Pioglitazone should not be used in patients with hepatic impairment.

Indication

Deculin is indicated as a combination therapy with sulfonylurea or metformin in patients with type 2 diabetes mellitus who are inadequately controlled on sulfonylurea and metformin monotherapy.